Eugenics, Environmental Ruin, and Surveillance: The Story of Silicon Valley
By Edward Ongweso Jr.,
The Nation
| 06. 23. 2023
In the opening pages of his magisterial Bay Area history, Imperial San Francisco, historian Gray Brechin presents his book as an attempt “to answer the question raised by the kind of cities we build today: Are they worth it?” It’s a deceptively simple question, and it reemerges when we discuss San Francisco and its discontents.
From the city’s earliest days, visionaries looked at San Francisco and saw an heir to Rome. Brechin points to Army scout John C. Frémont, who said he named the bay’s mouth “Chrysopylae (Golden gate) on “the same principle that the harbor of Byzantium (Constantinople afterwards) was called Chrysoceras (Golden horn).”
Brechin also discusses Emanuel Leutze, who painted a mural on a wall in the House wing of the Capitol called Westward the Course of Empire Takes Its Way, which depicts settlers seeing California for the first time. “To Leutze’s cultivated sensibility, these were more than settlers entering California,” Brechin writes, “they were both the Israelites entering Canaan and the holy family of the New World.” Brechin describes a party attended by Leutze where the painter...
Related Articles
By Hannah Devlin, The Guardian | 05.14.2024
Photo by Kind and Curious from Unsplash
When Great Ormond Street hospital (Gosh) published the results of its gene therapy trial for “bubble baby” syndrome it was hailed as a medical breakthrough. The treatment had a more than 95% success...
By Victoria Bisset and Adela Suliman, The Washington Post | 05.09.2024
Photo by CDC from Unsplash
A baby girl born with profound genetic deafness can now hear unaided after receiving a “groundbreaking” gene therapy trial, Britain’s National Health Service said Thursday.
Opal Sandy, an 18-month-old from Oxfordshire, England, is the first...
By Carrie Arnold, Nature Biotechnology | 04.17.2024
Tome Biosciences came out of stealth mode on 12 December with a haul of over $200 million to develop the company’s gene editing platform. Tome’s first order of business was to snap up Replace Therapeutics to expand its toolkit to...
By Rob Stein, NPR | 04.24.2024
Lisa Pisano was lying in a hospital bed at NYU Langone Health, hooked up to beeping monitors and an array of tubes. Her surgical wounds were still healing, and she looked tired. But the 54-year-old New Jersey woman said she...